目次

LIST OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING INCIDENCE OF CARDIOVASCULAR AND CORONARY ARTERY DISEASES
4.2.2 GROWING AWARENESS, EXPENDITURE, AND DEPENDENCE ON ANTICOAGULANTS
4.3 RESTRAINTS
4.3.1 STRINGENT REGULATORY NORMS
4.4 OPPORTUNITIES
4.4.1 INCREASING PATIENT POPULATION AND PATENT EXPIRY TO SUPPORT NEW PRODUCT LAUNCH

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.2.6 US AND GLOBAL NUMBER OF PATIENTS ON ANTICOAGULANTS (2019), IN MILLION
5.3 IMPACT OF COVID-19 ON THE ANTICOAGULATION MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON DEMAND FOR ANTICOAGULATION DRUGS
5.3.4 EFFECT 0F ANTICOAGULATION ON COVID-19 PATIENTS
5.4 PATENT EXPIRATION OF ALL KEY DOACS
5.4.1 INTRODUCTION

6 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS
6.1 OVERVIEW
6.2 DOACS
6.3 WARFARIN
6.4 OTHER VITAMIN K
6.5 LMWH

7 GLOBAL ANTICOAGULATION MARKET, BY DISEASE INDICATION
7.1 OVERVIEW
7.2 HEART ATTACK
7.3 STROKE
7.4 DVT/PE
7.5 MHV
7.6 OTHERS

8 GLOBAL ANTICOAGULATION MARKET, BY ROA
8.1 OVERVIEW
8.2 ORAL
8.3 INJECTABLE
8.4 OTHERS

9 GLOBAL ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL PHARMACY
9.3 HOSPITAL PHARMACIES
9.4 ONLINE PHARMACIES

10 GLOBAL ANTICOAGULATION MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 GLOBAL ANTICOAGULATION MARKET: COMPANY RANKING
11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 NEW PRODUCT LAUNCHES
11.6 FINANCIAL MATRIX

12 COMPANY PROFILES
12.1 PFIZER, INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 SANOFI
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 JOHNSON & JOHNSON SERVICES INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 GLAXOSMITHKLINE PLC
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 DAIICHI SANKYO COMPANY, LIMITED
12.5.1 COMPANY OVERVIEWS
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 BRISTOL-MYERS SQUIBB COMPANY
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 PORTOLA PHARMACEUTICALS, INC
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 NOVARTIS AG
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 F. HOFFMANN-LA ROCHE LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES

13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
?

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 LIST OF KEY DOACS AND THEIR PATENT EXPIRATION
TABLE 4 GLOBAL: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 5 GLOBAL: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 6 GLOBAL: ANTICOAGULATION MARKET, FOR DOACS, BY TYPE, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 7 GLOBAL: ANTICOAGULATION MARKET, FOR APIXABAN,BY DOACS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 8 GLOBAL: ANTICOAGULATION MARKET, FOR RIVAROXABAN,BY DOACS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 9 GLOBAL: ANTICOAGULATION MARKET, FOR EDOXABAN,BY DOACS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 10 GLOBAL: ANTICOAGULATION MARKET, FOR DABIGATRAN,BY DOACS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 11 GLOBAL: ANTICOAGULATION MARKET, FOR BETRIXABAN,BY DOACS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 12 GLOBAL: ANTICOAGULATION MARKET, FOR WARFARIN BY DRUG CLASS, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 13 GLOBAL: ANTICOAGULATION MARKET, OTHER VITAMIN K, BY DRUG CLASS 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 14 GLOBAL: ANTICOAGULATION MARKET, BY OTHER VITAMIN K, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 15 GLOBAL: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 16 GLOBAL: ANTICOAGULATION MARKET, FOR HEART ATTACK BY DISEASE INDICATION, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 17 GLOBAL: ANTICOAGULATION MARKET, FOR STROKEBY DISEASE INDICATION, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 18 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 19 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 20 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY DISEASE INDICATION, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 21 GLOBAL: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 22 GLOBAL: ANTICOAGULATION MARKET, FOR ORAL BY ROA, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 23 GLOBAL: ANTICOAGULATION MARKET, FOR INJECTABLEBY ROA, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 24 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY ROA, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 25 GLOBAL: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 26 GLOBAL: ANTICOAGULATION MARKET, FOR RETAIL PHARMACYBY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 27 GLOBAL: ANTICOAGULATION MARKET, FOR MEDICAL STOREBY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 28 GLOBAL: ANTICOAGULATION MARKET, FOR ONLINE PHARMACIESBY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION), BY REGION, 2017-2027 (USD MILLION)
TABLE 29 GLOBAL: ANTICOAGULATION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 NORTH AMERICA: ANTICOAGULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 31 NORTH AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 32 NORTH AMERICA: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION)
TABLE 33 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 34 NORTH AMERICA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 35 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 36 US ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 37 US: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION)
TABLE 38 US: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 39 US: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 40 US: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 41 CANADA ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 42 CANADA: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION)
TABLE 43 CANADA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 44 CANADA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 45 CANADA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 46 EUROPE: ANTICOAGULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 47 EUROPE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 48 EUROPE: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION)
TABLE 49 EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 50 EUROPE: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 51 EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 52 GERMANY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 53 GERMANY: ANTICOAGULATION MARKET, BY DOACS, 2017-2027 (USD MILLION)
TABLE 54 GERMANY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 55 GERMANY: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 56 GERMANY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 57 UK: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 58 UK: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 59 UK: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 60 UK: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 61 UK: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 62 FRANCE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 63 FRANCE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 64 FRANCE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 65 FRANCE: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 66 FRANCE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 67 ITALY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 68 ITALY: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 69 ITALY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 70 ITALY: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 71 ITALY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 72 SPAIN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 73 SPAIN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 74 SPAIN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 75 SPAIN: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 76 SPAIN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 77 REST OF EUROPE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 78 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 79 REST OF EUROPE: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 80 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 81 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 82 ASIA-PACIFIC: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%)
TABLE 83 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 84 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 85 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 86 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 87 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 88 CHINA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 89 CHINA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 90 CHINA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 91 CHINA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 92 CHINA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 93 INDIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 94 INDIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 95 INDIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 96 INDIA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 97 INDIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 98 JAPAN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 99 JAPAN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 100 JAPAN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 101 JAPAN: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 102 JAPAN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 103 AUSTRALIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 104 AUSTRALIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 105 AUSTRALIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 106 AUSTRALIA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 107 AUSTRALIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 108 SOUTH KOREA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 109 SOUTH KOREA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 110 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 111 SOUTH KOREA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 112 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 113 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 114 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 115 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 116 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 117 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 118 REST OF THE WORLD: ANTICOAGULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)
TABLE 119 REST OF THE WORLD: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%)
TABLE 120 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 121 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 122 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 123 REST OF THE WORLD: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 124 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 125 MIDDLE EAST: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 126 MIDDLE EAST: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 127 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 128 MIDDLE EAST: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 129 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 130 AFRICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 131 AFRICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 132 AFRICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 133 AFRICA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 134 AFRICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 135 LATIN AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION)
TABLE 136 LATIN AMERICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017-2027 (USD MILLION)
TABLE 137 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017-2027 (USD MILLION)
TABLE 138 LATIN AMERICA: ANTICOAGULATION MARKET, BY ROA, 2017-2027 (USD MILLION)
TABLE 139 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017-2027 (USD MILLION)
TABLE 140 MAJOR MANUFACTURERS RANKING, 2019
TABLE 141 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE ANTICOAGULATION MARKET
TABLE 142 NEW PRODUCT LAUNCHES
TABLE 143 PFIZER, INC: PRODUCTS/SERVICES OFFERED
TABLE 144 SANOFI: PRODUCTS/SERVICES OFFERED
TABLE 145 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED
TABLE 146 JOHNSON & JOHNSON SERVICES INC: KEY DEVELOPMENTS
TABLE 147 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED
TABLE 148 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS/SERVICES OFFERED
TABLE 149 DAIICHI SANKYO COMPANY, LIMITED: KEY DEVELOPMENTS
TABLE 150 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED
TABLE 151 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS
TABLE 152 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 153 PORTOLA PHARMACEUTICALS, INC: PRODUCTS/SERVICES OFFERED
TABLE 154 PORTOLA PHARMACEUTICALS, INC: KEY DEVELOPMENTS
TABLE 155 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
TABLE 156 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
?

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 ANTICOAGULATION MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANTICOAGULATION MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: ANTICOAGULATION MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: ANTICOAGULATION MARKET
FIGURE 9 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS, 2019 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: ANTICOAGULATION MARKET, USAGE, 2019 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: ANTICOAGULATION MARKET, ROA, 2019 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: ANTICOAGULATION MARKET, DISTRIBUTION CHANNEL, 2019 & 2027 (USD MILLION)
FIGURE 13 GLOBAL: ANTICOAGULATION MARKET, BY REGION 2019 & 2027 (USD MILLION)
FIGURE 14 GLOBAL: ANTICOAGULATION MARKET SHARE, BY REGION 2019 (%)
FIGURE 15 NORTH AMERICA: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%)
FIGURE 16 EUROPE: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 18 SALES & OPERATING INCOME, 2019
FIGURE 19 R&D EXPENDITURE, 2019
FIGURE 20 PFIZER, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 PFIZER, INC: SWOT ANALYSIS
FIGURE 22 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 SANOFI: SWOT ANALYSIS
FIGURE 24 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS
FIGURE 26 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
FIGURE 28 DAIICHI SANKYO COMPANY, LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 DAIICHI SANKYO COMPANY, LIMITED: SWOT ANALYSIS
FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS
FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 34 PORTOLA PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 PORTOLA PHARMACEUTICALS, INC: SWOT ANALYSIS
FIGURE 36 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 NOVARTIS AG: SWOT ANALYSIS
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS